SVRA: Rega marang dodolan Savara Corp
Savara Inc. aims for dominance in the therapy of rare pulmonary proteinosis by implementing targeted delivery of biologics to inflammation sites. The GURU.Markets portal displays this P/S time series, where the metric value of captures the current revenue valuation. Since the company is in the pre-commercial stage, future price momentum depends directly on final regulatory decisions.
Rincian analitis perusahaan Savara Corp (SVRA)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Savara Inc.|SVRA - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Savara Pharma|SVRA - Utang perusahaan|Rasio utang marang aset resik Savara Corp|SVRA - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Savara|Rasio jangkoan perantara savarapharma.com
- data bathi resik lan rasio valuasi:
SVRA - Bathi resik|Prakiraan bathi perusahaan Savara Inc.|SVRA - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep Savara Inc|SVRA - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Savara Corp|SVRA - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Savara|SVRA - Bathi saben saham sajrone rolas wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan savarapharma.com|SVRA - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Savara Inc.
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:savarapharma.com, SVRA
The P/S ratio is calculated as the ratio of Savara Inc. (SVRA) market capitalization to its annual revenue, determining the value of one dollar of sales in the eyes of investors. Analyzing the price-to-sales ratio allows for an assessment of the efficiency of biopharmaceutical logistics costs, where the stability of clinic supplies directly impacts the asset's fundamental resilience and the justification of current market valuations.
Perusahaan pesaing
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Protagonist Corp PTGX|IMVT: Multiplikator P/S|kiniksa.com (KNSA) - Multiplikator P/S|Kapitalisasi marang pendapatan GRFS|Rasio rega marang pendapatan ADPT|Multiplikator P/S CLDX|Multiplikator P/S Aurinia Corp (AUPH)|Rasio rega marang pendapatan BioCryst BCRX|Rasio kapitalisasi pasar marang pendapatan VERA|Dianthus Therapeutics, Inc. - Multiplikator P/S|PHVS - Multiplikator P/S|ABCL (AbCellera Biologics Inc) - Kapitalisasi marang pendapatan|Tourmaline - Rasio kapitalisasi pasar marang pendapatan|PGEN (Precigen, Inc.) - Multiplikator P/S|pharming.com (PHAR) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Nektar Therapeutics Inc. (NKTR)|Upstream Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ZBIO (Zenas Biopharma, Inc.)|IMNM - Kapitalisasi marang pendapatan|GOSS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan kalvista.com KALV|Septerna (SEPN) - Rasio rega marang pendapatan|PVLA - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan RIGL|Rasio rega marang pendapatan ANAB|Rasio rega marang pendapatan Astria Therapeutics (ATXS)|ENGN (engene.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S RAPT (RAPT Therapeutics)|Multiplikator P/S Aerovate Therapeutics, Inc. JBIO|ACRS - Rasio rega marang pendapatan|Rasio rega marang dodolan KYTX|TLSA: Multiplikator P/S|cabalettabio.com - Rasio kapitalisasi pasar marang pendapatan|VTYX (Ventyx Biosciences, Inc.) - Multiplikator P/S|Multiplikator P/S Theratechnologies, Inc.|Rasio rega marang pendapatan Avalo Therapeutics Inc. (AVTX)|ELDN (Eledon Pharmaceuticals, Inc) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Agenus AGEN|CLYM - Kapitalisasi marang pendapatan|Zura Bio - Multiplikator P/S|ATYR - Multiplikator P/S|ADAG (adagene.com) - Kapitalisasi marang pendapatan|Ikena Oncology - Rasio kapitalisasi pasar marang pendapatan|STTK (Shattuck Labs Inc) - Multiplikator P/S|Equillium Bio (EQ) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Connect Biopharma (CNTB)|Kapitalisasi marang pendapatan immunic-therapeutics.com IMUX|Rasio rega marang pendapatan Atara Bio ATRA|IFRX - Kapitalisasi marang pendapatan|XFOR: Kapitalisasi marang pendapatan|ACET - Multiplikator P/S|celularity.com (CELU) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan INMB|BRNS (Barinthus Bio) - Multiplikator P/S|Rega marang dodolan Kezar Life Sciences Inc KZR|Rasio rega marang pendapatan SAB Biotherapeutics (SABS)|Koefisien rega marang pendapatan akaritx.com|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd.)|Multiplikator P/S Q32 Bio Inc QTTB|GOVX: Kapitalisasi marang pendapatan|EDSA: Rasio rega marang pendapatan|IBIO: Multiplikator P/S|Carisma Therapeutics Inc. (CARM) - Multiplikator P/S|Rasio rega marang pendapatan XTL Biopharmaceuticals Ltd.|BOLT: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HCWB|Multiplikator P/S aptevotherapeutics.com (APVO)|AIM ImmunoTech Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ADTX|GRI Bio - Multiplikator P/S|Koefisien rega marang pendapatan XORTX Therapeutics Inc XRTX|ReShape Lifesciences (HIND) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan REVB|INDP (Indaptus Therapeutics) - Multiplikator P/S|Kapitalisasi marang pendapatan scinai.com (SCNI)|Kapitalisasi marang pendapatan CALI (CalciMedica, Inc.)|Koefisien rega marang pendapatan affimed.com|Rasio rega marang pendapatan Allakos ALLK|Koefisien rega marang pendapatan HOOKIPA Pharma, Inc. (HOOK)|IGMS: Kapitalisasi marang pendapatan|ITOS: Rasio rega marang pendapatan|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|TC BioPharm (Holdings) Plc - Rasio kapitalisasi pasar marang pendapatan|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
